World's Largest Antibody and Recombinant Protein Manufacturer Abnova is the first biotech company successfully integrated the IT-style management and industrial-scale antibody manufacturing. Founded in 2002 at the height of the genomic era, Abnova‘s vision is the production and application of antibodies derived from the “one gene one antibody” translation of entire human genome. The company’s first goal is to vastly expand the scope and availability of antibody reagents for the research market by taking a genome-wide approach to the high throughput production of human protein and antibody. As such, Abnova has produced 19,000+ recombinant proteins, 12,000+ MaxPab antibodies, 16,000+ monoclonal antibodies, and 20,000+ polyclonal antibodies targeting the human genome. Since 2009, Abnova has diversified into the systems arena focusing on antibody pairs, ELISA kits, instrumentations for biomarker screening and protein quantification in the short-term (1-3 years), diagnostic development concentrating on infection, cancer, endocrine and metabolism in the mid-term (3-5 years), and drug development specializing on CD molecule and GPCR monoclonal antibody in the long-term (5-7years).